pre-IPO PHARMA

COMPANY OVERVIEW

Mitobridge is dedicated to delivering therapeutics that improve mitochondrial function. Our team of experienced drug discovery and development scientists is leveraging their exceptional knowledge of mitochondria biology to develop a pipeline of innovative programs for the treatment of kidney and muscle diseases with high unmet medical need.


LOCATION

  • None, , None

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.mitobridge.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    longwood-fund


    PRESS RELEASES


    Nov 2, 2022

    OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company


    Jan 23, 2018

    Astellas Completes Acquisition of Mitobridge, Inc.


    Nov 30, 2017

    Astellas Acquires Mitobridge Under Existing Collaboration


    Nov 6, 2017

    Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARδ Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting


    Sep 18, 2017

    Mitobridge Adds NAD+ Modulation as a Therapeutic Approach for Improving Mitochondrial Function


    For More Press Releases


    Google Analytics Alternative